seattletimes.com

seattletimes.com
Share

seattletimes.com

 •  September 21

COLUMBUS, Ohio (AP) — A member of the famed Tuskegee Airmen is joining other military veterans in supporting a fall ballot measure in Ohio that would bar state agencies from buying drugs at prices higher than those paid by the Department of Veterans Affairs. Don Elder attended a Statehouse news conference Thursday organized by the vote-yes...

seattletimes.com

 •  June 26

Seattle Genetics is announcing Monday results of a clinical trial showing patients with advanced Hodgkin lymphoma do better when its drug Adcetris replaces one of the four drugs in the current first-line treatment for the cancer. That sets the stage for seeking Food and Drug Administration approval for the treatment “as soon as possible,” said Clay...

seattletimes.com

 •  June 19

Seattle Genetics said it is discontinuing a Phase 3 clinical trial after data showed “a higher rate of deaths, including fatal infections” in acute myeloid leukemia patients receiving its drug than in the study’s other patients. As a result of the data it received June 16, the company said Monday, Seattle Genetics is suspending patient enrollment...

seattletimes.com

 •  April 14

Seattle-based M3 Biotechnology has raised $12 million from investors, and plans to use the funds to start clinical trials for a drug that seeks to reverse the effects of Alzheimer’s disease. The startup has licensed technology developed over more than a decade at Washington State University, and has been working for the past three years to develop...

seattletimes.com

 •  March 1

Juno Therapeutics is shutting down the clinical trial of one of its cancer drugs, three months after it was put on hold following patient deaths. The Seattle biotech will permanently stop the “Rocket” trial of JCAR015 to treat acute lymphoblastic leukemia (ALL) in adults. “We have decided not to move forward … at this time, even though it generated...